The Journal of
Clinical Psychiatry

Tardive Dyskinesia

Educational Activity December 17, 2019

FDA-Approved Medications to Treat Tardive Dyskinesia

Joseph P. McEvoy, MD

J Clin Psychiatry 2020;81(1):NU18041BR3C

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

About the Authors

Joseph P. McEvoy, MD

View full profile

Save

Cite

Read the Current Issue

Original Research

Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum

Original Research

Valbenazine in Elderly Adults With Tardive Dyskinesia

Academic Highlights

Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report

Original Research

Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study

Consensus Statement

Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations

Brief Report

Psychosocial Correlates of Optimism among US Military Veterans

View current Issue

Educational Activity

Evaluating Patients for TD

December 1, 2020

Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity,...

Andrew A. Nierenberg

Educational Activity

Treatment Strategies for Tardive Dyskinesia

December 24, 2019

What steps do you take when patients exhibit tardive dyskinesia? Are you familiar with treatment guidelines and data on approved and non-approved strategies? Explore recommendations from Dr Daniel Kremens.

Daniel E. Kremens

Educational Activity

Parkinson Disease Treatment

June 26, 2018

Although levodopa is effective for treating Parkinson disease, physicians and patients face significant management challenges related to disease progression. Patients may develop fluctuations in motor symptoms and dyskinesias as...

Adolfo Ramirez-Zamora

FDA-Approved Medications to Treat Tardive Dyskinesia

About the Authors

Read the Current Issue

Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum

Valbenazine in Elderly Adults With Tardive Dyskinesia

Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report

Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study

Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations

Psychosocial Correlates of Optimism among US Military Veterans

ELSEWHERE:

FOLLOW US:

FDA-Approved Medications to Treat Tardive Dyskinesia

Free Access: Please Log In

About the Authors

Read the Current Issue

Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum

Valbenazine in Elderly Adults With Tardive Dyskinesia

Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report

Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study

Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations

Psychosocial Correlates of Optimism among US Military Veterans

Related Articles

Evaluating Patients for TD

Treatment Strategies for Tardive Dyskinesia

Parkinson Disease Treatment

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles